WARRINGTON, Pa., April 17, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage ...
Windtree Therapeutics Reports First Quarter 2025 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., May 16, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or “the Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company ...
WindTree Therapeutics has the clinical results it wants—but is missing the bull market, meaning the biotech is exploring strategic options. Amid the market downturn, the biotech is considering a ...
Windtree Therapeutics is heading back to the licensing well, using a familiar bucket to reel in more biobucks. The biotech is handing over greater China and Asia Pacific rights to Lee’s Pharma for ...
Windtree Therapeutics Inc (NASDAQ:WINT) shares are trading higher by 36.5% to $2.03 during Monday’s session after the company regained compliance with Nasdaq’s minimum bid price requirement, ensuring ...
WARRINGTON, Pa., March 31, 2020 /PRNewswire/ -- Windtree Therapeutics, Inc. (OTCQB: WINT), a biotechnology and medical device company focused on developing drug product candidates and medical device ...
Windtree Therapeutics, Inc. (NASDAQ:WINT) shares are trading higher on Thursday after the company entered a license and supply agreement with Evofem Biosciences, Inc. What To Know: Under the agreement ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results